Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INC Research Holdings Inc (INCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: INCR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 11.36% | Avg. Invested days 40 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.22M USD | Price to earnings Ratio - | 1Y Target Price 33.56 |
Price to earnings Ratio - | 1Y Target Price 33.56 | ||
Volume (30-day avg) - | Beta 0.58 | 52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 |
52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.39% | Operating Margin (TTM) -86.82% |
Management Effectiveness
Return on Assets (TTM) -7.09% | Return on Equity (TTM) -17.03% |
Valuation
Trailing PE - | Forward PE 6.94 | Enterprise Value 120187421 | Price to Sales(TTM) 0.34 |
Enterprise Value 120187421 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 5.29 | Shares Outstanding 54512600 | Shares Floating 27296363 |
Shares Outstanding 54512600 | Shares Floating 27296363 | ||
Percent Insiders 30.2 | Percent Institutions 5.38 |
Upturn AI SWOT
INC Research Holdings Inc
Company Overview
History and Background
Note: INC Research Holdings, Inc. was acquired and is no longer a publicly traded entity under that name. It merged with inVentiv Health to form Syneos Health (SYNH). The following information pertains to INC Research Holdings prior to the merger.
Core Business Areas
- Clinical Development Services: Management and execution of clinical trials, including Phase I-IV studies. This includes study design, site selection, patient recruitment, data management, and regulatory submissions.
- Central Laboratory Services: Provides a wide range of laboratory testing services to support clinical trials, including safety testing, biomarker analysis, and pharmacokinetic/pharmacodynamic assessments.
- Consulting Services: Offers strategic consulting services to pharmaceutical and biotechnology companies related to clinical development, regulatory strategy, and market access.
Leadership and Structure
Prior to the merger, INC Research was led by a management team with expertise in clinical research, drug development, and business operations. The organizational structure was based on functional departments supporting the different business segments.
Top Products and Market Share
Key Offerings
- Full-Service Clinical Trials: Comprehensive management of clinical trials, from study design to final report. Market share data prior to merger is difficult to isolate, but they were a significant player in the CRO market. Competitors: IQVIA, LabCorp, PPD (now Thermo Fisher).
- Central Lab Testing: Laboratory testing services for clinical trials. This is a highly competitive market with other large CROs offering similar services. Competitors: LabCorp, Quest Diagnostics, ICON.
- Phase I-IV clinical trial services: From initial dose escalation, through commercialization and post-market studies, INC offered full support for a range of clients, therapeutic areas and geographies. Competitors: IQVIA, PPD, Covance (now LabCorp).
Market Dynamics
Industry Overview
The Clinical Research Organization (CRO) industry is large and fragmented, with a high need for outsourcing. Companies in the pharmaceutical and biotechnology industries outsource clinical trial activities to CROs to reduce costs, accelerate development timelines, and access specialized expertise.
Positioning
Prior to the merger, INC Research was positioned as a mid-sized CRO focused on providing high-quality clinical development services to pharmaceutical and biotechnology companies. They focused on building strong relationships with their clients and delivering results-oriented solutions.
Total Addressable Market (TAM)
The global CRO market is in the hundreds of billions USD. Pre-merger INC captured a small, but significant portion, and post-merger Syneos has enhanced this position.
Upturn SWOT Analysis
Strengths
- Strong client relationships
- Expertise in clinical development
- Global presence
- Focus on quality and execution
- Financial Stability
Weaknesses
- Smaller size compared to industry giants
- Dependence on pharmaceutical and biotechnology spending
- Integration risk associated with past acquisitions
- Potential issues with project mismanagement
Opportunities
- Growing demand for outsourced clinical development services
- Increasing complexity of clinical trials
- Expansion into emerging markets
- Strategic acquisitions to expand service offerings
- Increasing regulatory requirements
Threats
- Intense competition from larger CROs
- Economic downturn impacting pharmaceutical spending
- Changes in regulatory requirements
- Patent expiration impacting drug development pipelines
- Failure to comply with regulatory and ethical standards
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
Competitive Landscape
The CRO industry is highly competitive, with a mix of large global players and smaller niche providers. Syneos Health (post INC merger) competes on the basis of its comprehensive service offerings, global reach, and ability to deliver high-quality clinical development solutions.
Major Acquisitions
inVentiv Health
- Year: 2017
- Acquisition Price (USD millions):
- Strategic Rationale: Merger of equals to create a fully integrated biopharmaceutical solutions organization, Syneos Health. This combined clinical and commercial expertise to provide a more comprehensive offering to clients.
Growth Trajectory and Initiatives
Historical Growth: Prior to the merger, INC Research experienced solid growth driven by the increasing demand for outsourced clinical development services.
Future Projections: Not applicable, as INC Research no longer exists as an independent publicly traded entity.
Recent Initiatives: Prior to the merger, INC Research focused on expanding its service offerings, strengthening its client relationships, and growing its global presence. The merger with inVentiv Health was a major strategic initiative.
Summary
INC Research Holdings Inc. was a mid-sized CRO that had a strong focus on client relationships and expertise in clinical development. The merger with inVentiv Health was a strategic move to create a larger, more comprehensive biopharmaceutical solutions organization (Syneos Health). While INC Research's independent financial data is no longer available, its contribution to Syneos Health has enhanced the company's competitive positioning. Moving forward, it is important to look at Syneos' performance for any continued insight from the legacy of the INC Research component and to monitor the integration process and market dynamics to ensure continued growth and success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (prior to merger)
- Industry Reports
- Market Research Reports
- Publicly Available Information
Disclaimers:
This analysis is based on publicly available information and represents a snapshot of INC Research Holdings Inc. prior to the merger. Forward-looking statements are based on assumptions and subject to uncertainties. The analysis does not constitute investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INC Research Holdings Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-11-07 | CEO & Chairman Mr. Alexander Rabinovich | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 320 | Website https://www.intercure.co |
Full time employees 320 | Website https://www.intercure.co | ||
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.